Abstract: Disclosed herein is a skin whitening composition that includes, based on a total volume of the skin whitening composition, 0.5 ?M to 10 ?M of resveratrol, and 2.5 ?M to 500 ?M of nicotinamide mononucleotide.

Abstract: A process for the manufacture of a skin ointment includes creating a eutectic mixture that includes an oleic acid; and adding water that is preheated to 178 degrees F. directly into the eutectic mixture at 178 degrees F. A skin ointment that includes 10-14% oleic acid; 7-11% palmitic acid; 7-11% stearic acid; 6-10% cetearyl alcohol; 1-3% boric acid 99%+; 1-2% bismuth sub carbonate 99%+; and the remaining part being purified water. A 2 oz skin ointment portion that includes 3.18 g oleic acid; 2.47 g palmitic acid; 2.47 g stearic acid; 2.18 g cetearyl alcohol; 0.61 g boric acid 99%+; 0.32 g bismuth sub carbonate 99%+; and 16.11 g Purified Water.

Abstract: Suggested is a method for fighting microorganisms responsible for causing body odour and/or being detrimental for oral health encompassing or consisting of the following step: (i) providing a composition comprising or consisting of at least one menthol derivative selected from the group consisting of menthyl ethers menthone glyceryl acetal, menthone glyceryl ketal or mixtures of both, menthyl esters, menthyl carbonates, semiesters of menthols with dicarboxylic acid or their amides and mixtures thereof; and (ii) applying a working amount of said composition to human skin and/or oral cavity.

Abstract: A composition comprising: (i) 0.01 to 10 wt % of a branched cationic conditioning surfactant; selected from structure 1, wherein: ?R1 and R2 comprise linear or branched alkyl chains, saturated or unsaturated, with carbon-carbon chain lengths of from C6 to C22; preferably from C6 to C12; ?n has a range of from 1 to 6; ?R3 comprises an alkyl chain having a carbon-carbon chain length of from C1 to C4, preferably C1 to C2; ?R4 comprises a proton or an alkyl chain having a carbon-carbon chain length of from C1 to C4, preferably C1 to C2; and ?X is an organic or inorganic anion; (ii) 0.1 to 10 wt % of a linear fatty material; (iii) 0.1 to 5 wt % of a structurant; and (iv) a particulate benefit agent selected from conditioning actives; wherein the molar ratios of branched cationic surfactants (i) to linear fatty material (ii) are in the range of from from 1:10 to 1:1, most preferably 1:5 to 1:2 results in improved particulate benefit agent deposition onto bleached hair.

Abstract: The invention relates to a composition comprising the combination of at least one fatty substance, the total content of fatty substance being greater than or equal to 30% by weight, relative to the total weight of the composition, at least one particular carboxylic acid and at least one oxidation dye and/or an alkaline agent.

Abstract: The use of lipo-amino acid alkyl esters as SPF (Sun Protection Factor) boosters in cosmetic compositions containing a sun filter is described. The alkyl esters, when added to cosmetic compositions containing a sun filter, increase their SPF value by 50% or higher. As a result, the amount of sun filter in the cosmetics can be significantly reduced while maintaining a high SPF. The SPF booster effect was observed in different types of cosmetic compositions and with different sun filters. The alkyl esters have a strong natural connotation and can be obtained by eco-friendly synthesis methods. Photoprotective cosmetic compositions are thereby obtained which are safe to use and have better acceptance by the consumer.

Abstract: A subject of the present invention is a cosmetic composition comprising 6-hydroxy benzomorpholine of formula (II), hydroxyethyl-3,4-methylenedioxyaniline of formula (III) and at least one nonionic surfactant of alkylpolyglycoside type. The present invention also relates to a process for dyeing keratin fibres, such as the hair, wherein the composition as described previously is applied to said fibres. Another subject of the present invention is the use of the composition according to the invention for dyeing keratin fibres such as the hair.

Abstract: The present invention relates to cosmetic composition comprising the UV-filter Bisoctrizole, a C8-C16 alkyl poly-glucoside, a mixture of branched and linear saturated C15-C19, wherein said mixture comprised primarily branched saturated C15-C19, and an specific dialkyl ether or (di)ester. This cosmetic composition shows an increased water resistance of the sun protecting factor.

Abstract: A fiber-treating agent, including a condensate formed from the following components (A) and (B), and a component (C), and has a turbidity of 1,000 NTU or less: (A): formaldehyde or a hydrate thereof, (B): triazine or a derivative thereof of formula (1): where R1 to R3 are the same or different, and each represent a hydrogen atom, a hydroxymethylamino group, an amino group, a hydroxy group, a halogen atom, a phenyl group, a linear or branched alkyl group or alkenyl group having 1 or more and 6 or less carbon atoms, or a linear or branched alkoxy group or alkenyloxy group having 1 or more and 6 or less carbon atoms, and (C): water.

Abstract: The invention relates to a composition comprising at least one oxidation coupler chosen from hydroxyethyl-3,4-meth-lenedioxyaniline of formula (I), one of its addition salts, its solvates and/or the solvates of its salts, at least one oxidation coupler chosen from 2-amino-5-ethylphenol of formula (II), one of its addition salts, its solvates and/or the solvates of its salts, and at least one compound chosen from N,N-dicarboxymethyl glutamic acid, one of its salts and mixtures thereof. The invention also relates to a process for dyeing keratin fibres, preferably the hair, comprising the application of the composition to said keratin fibres.

Abstract: This composition for the oral cavity contains an amino acid and a specific sugar. The specific sugar is at least one selected from lactose, 2?-fucosyllactose, galactose, raffinose, and a galactooligosaccharide.

Abstract: A cosmetic method for balancing the skin microbiota. The cosmetic method includes the application to all or part of the skin, skin appendages and/or mucous membranes of at least one short-chain fructo-oligosaccharide and at least one native starch. Also, a cosmetic composition, which includes, in a cosmetically acceptable carrier, at least one short-chain fructo-oligosaccharide and at least one native starch.

Abstract: A soft-focus cosmetic composition contains at least one natural oil, at least one blurring agent, and at least one water-in-oil emulsifier. The soft-focus cosmetic composition may be a water-in-oil emulsion, where at least one natural oil is in the external phase. The soft-focus cosmetic composition has good radiance. A method for reducing the appearance of skin imperfections by applying to skin surfaces a soft-focus composition comprising at least one natural oil, at least one blurring agent, and at least one water-in-oil emulsifier.

Abstract: An emulsion component includes a polyglycerol ester-base emulsifier and a polyglycerol ester-based coemulsifier. The polyglycerol ester-base emulsifier has a hydrophilic-lipophilic balance value greater than 10, and is formed by reacting a first polyglycerol having a degree of polymerization ranging from 4 to 20 with a first acid. The polyglycerol ester-based coemulsifier has a hydrophilic-lipophilic balance value not greater than 10, and is formed by reacting a polyol with a second acid. The polyol is selected from the group consisting of a glycerol and a second polyglycerol having a degree of polymerization ranging from 2 to 10. In addition, a weight ratio of the polyglycerol ester-based emulsifier and the polyglycerol ester-based coemulsifier ranges from 0.75 to 8. An oil-in-water sunscreen product including the emulsion component and an oil-in-water sunscreen lotion including the emulsion component are also provided.

Abstract: The present disclosures are directed to personal care compositions comprising crosslinked silicone elastomer; personal care compositions comprising a crosslinked silicone elastomer powder that is free of surfactant; and personal care compositions that are free of a polyether compound. The present disclosures are further directed to personal care compositions comprising one or more of oils, an aqueous phase, sunscreens, film formers, waxes, emulsifiers, particulates, pigments, dyes, and preservatives.

Abstract: Provided are silicone elastomer particles that have higher oil absorbency than conventional products and are less prone to aggregation, making the particles superior in handling workability as a cosmetic raw material and imparting a superior tactile sensation and feel during use to a cosmetic product. Specifically, silicone elastomer particles, having a structure in which at least two silicon atoms in a silicone elastomer particle are crosslinked by a divalent organic group having a partial structure formed by radical polymerization of vinyl acetate, as expressed by —{CH2—CH(COOCH3)}t— (where t is 1 or more), as well as a use thereof, are provided. In particular, the silicone elastomer particles have a crosslinked structure that is active with respect to biodegradability. Therefore, primary particles thereof are expected to have a property of disintegrating with the generation of non-crosslinked siloxane molecules due to a decomposition reaction of microorganisms and the like in the natural world.

Abstract: A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: A stretch film for use in the cosmetic or agri-food packaging sectors comprises konjac and carrageenan in a mass ratio of between 20/80 and 60/40. A stretch film according to the present disclosure has advantageous properties for use as a biodegradable stretch cling film and cosmetic mask.

Abstract: The aspects presented herein provide improved flavor compositions, able to deliver long lasting cooling sensation without compromising on the safety profile towards the skin and/or mucosal membrane.

Abstract: According to an exemplary embodiment of the present disclosure, a cosmetic composition comprising a fermented grape extract obtained by fermenting grape (Vitis vinifera) berries using fungus of the genus Botrytis is disclosed.

Abstract: A composition including a fermented propolis extract as an active ingredient and a method of preparing same. The composition including a fermented propolis extract as an active ingredient, according to the present invention, can be used for various applications such as improvement in skin wrinkles or skin elasticity, skin whitening, skin moisturizing, and skin antioxidant or anti-inflammatory applications. In addition, the composition can exhibit stronger effects due to the content of artepillin C that is increased by a preparation method according to the present invention.

Abstract: A method of preventing progression of an appearance or effect of aging in a subject is provided. A method of preventing, limiting, or inhibiting injury to skin integrity in a subject is also provided. A method of substantially maintaining a state of skin integrity in a subject is further provided. A method of preventing a topographical change of a cutaneous layer of skin in a subject is still further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided.

Abstract: A stable pharmaceutically formulation containing antibody, a buffer, a non-ionic surfactant, and a lyoprotectant/cryoprotectants. Also disclosed are associated methods for preparing, storing, and using such formulations.

Abstract: Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Examples of the diseases include, but not limited to, ocular neovascularization, neovascular glaucoma, vascular leak, macular edema, and a neovascular age-related macular degeneration.

Abstract: The present invention relates to a topical composition comprising pirfenidone and process to prepare the same. The present invention also relates to use of the topical composition comprising pirfenidone in the treatment of skin disorders of the dermis of fibrous or inflammatory origin.

Abstract: Slurries comprise liquid water, about 2% to about 70% ice by volume, and one or more additives affecting flowability and/or tonicity of the slurry. Solutions for making a slurry comprise liquid water and one or more additives affecting flowability of the slurry. Flowability of the slurry relates to ice particles capable of flowing through a cannula, such as a needle. The slurry is suitable for injection into subcutaneous fat of a human subject for removal of adipose tissue.

Abstract: Disclosed herein are methods for treatment of a skin disorders using pharmaceutical compositions that reduces the expression of and/or inhibit the activity of various genes including chemokine (C-X-C motif) ligands such as CXCL13 and XCL1, and matrix-metalloproteinases such as MMP12 and MMP13. The pharmaceutical compositions effectively act on epidermal differentiation and proliferation as well as on innate and adaptive immune cells in pathogenesis of skin disorders such as acne.

Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.

Abstract: In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Abstract: Provided herein are solutions and dried forms of extracellular vesicles (EVs) that are useful as therapeutic agents, and therapeutic compositions thereof.

Abstract: The present invention relates to a parenteral lyophilized formulation of duloxetine or a pharmaceutically acceptable salt thereof. Further, this invention relates to duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers, and other pharmaceutically acceptable excipients and subsequently lyophilized. The invention also describes combination formulation of Duloxetine with other active ingredients.

Abstract: The present application relates to a tablet formulation composition comprising granules prepared from a triazolopyrazine derivative represented by formula 1 as a drug substance, an excipient, a binder and a disintegrant, and, more particularly, is an invention that solves problems in drug production caused by poor flowability and tabletability of the triazolopyrazine derivative represented by formula 1, and relates to a tablet formulation composition with improved stability formed by comprising mannitol as an excipient and low-substituted hydroxypropyl cellulose as a binder, and a method for preparing the same.

Abstract: This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

Abstract: The present disclosure provides an improved yeast particle encapsulated nano-silica delivery system. The disclosure further provides methods of making and methods of using a nano-silica yeast particle delivery system.

Abstract: The present invention relates to electrospun fibers comprising i) a hydrophilic polymer that is soluble in a first solvent, ii) a bioadhesive substance that is slightly soluble in said first solvent, iii) optionally, a drug substance.

Abstract: An object of the present invention is the preparation and use of a new dry emulsion (DE) containing mitotane and its use for the oral route for the treatment of adrenocortical carcinoma, congenital adrenal hyperplasia and Cushing's syndrome.

Abstract: A method of treatment for individuals suffering from chronic primary or secondary refractory chronic insomnia by administration of Diprivan/Propofol, to move a patient through the stages of sleep such that the patient obtains sufficient adequate rest.

Abstract: The disclosure provides methods of treating a tissue, organ, organoid or organ culture, the method comprising treating a tissue, organ, organoid or organ culture in vitro with a composition comprising one or more cell turnover factors produced by cells exposed to a stress condition. The disclosure also provides methods of increasing regeneration of a tissue in an organ of a subject, the method comprising administering to the subject a composition comprising one or more cell turnover factors produced by cells exposed to a stress condition, wherein the composition is administered to the subject in an amount sufficient to increase regeneration of the tissue relative to a subject that is not treated with the composition.

Abstract: The present application provides a use of mitoxantrone hydrochloride liposome in the preparation of a medicament for treating ovarian cancer, gastric cancer or head and neck squamous cell carcinoma, a method for treating ovarian cancer, gastric cancer or head and neck squamous cell carcinoma using a mitoxantrone hydrochloride liposome formulation, and a mitoxantrone hydrochloride liposome formulation for treating ovarian cancer, gastric cancer or head and neck squamous cell carcinoma.

Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Abstract: A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

Abstract: Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.

Abstract: The present invention relates to a substance of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament. Further, the invention relates to the substance of formula (I) for use in the therapy of amyotrophic lateral sclerosis. Still further, the invention relates to a method of treating amyotrophic lateral sclerosis comprising administering to a subject in need thereof an effective amount of the substance of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.

Abstract: Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.

Abstract: A method of treating and preventing a neurodegenerative disorder associated with misfolding of ?-synuclein is provided in a patient at risk for a neurodegenerative disorder or having symptoms of a neurodegenerative disorder, comprising the administration of a combination of two or more drugs selected from a chemical chaperone class of drugs, glycolysis enhancer class of drugs, a bile acid class of drugs, a glucagon-like-peptide-1 agonist (GLP-1) class of drugs, a glucocerebrosidase (GCase) inducer class of drugs, an iron chelator class of drugs, a mitochondrial antioxidant class of drugs, and a cluster-Abelson (c-Abl) tyrosine kinase inhibitor class of drugs. Specifically, the combination of drugs may include two or more drugs selected from sodium phenylbutyrate (PBA), tauroursodeoxycholic acid (TUDCA), exenatide (EXD), deferiprone (DFP), terazosin (TZ), creatine (CR), CoQ10, Ambroxol (AMB), and nilotinib (NL). The PBA may be provided in an extended-release formulation.

Abstract: The present invention aids to correct erectile dysfunction by increasing blood circulation on the skin when applied topically. This composition is made with all organic food grade ingredients in form of a lotion than when rubbed on the skin, in a time-controlled fashion, is nutrition for the skin.

Abstract: Described herein are pet food compositions comprising an amino acid component comprising: lysine; betaine; and glutamic acid and/or a salt thereof present in an amount of about 7 wt. % or more, based on the total weight of the pet food composition; and about 3.3 wt. % or more, of a fatty acid component comprising a fatty acid having an aliphatic tail of 6 to 12 carbons and/or an omega-3 fatty acid, based on the total weight of the pet food composition.